
CLAIMS

WHAT IS CLAIMED IS:

1. A compound represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof, wherein:


R^a is -F, methoxy, methyl or ethyl;

R_4 is –H, methyl, ethyl, 2-methoxyethyl or $-CH_2CONH_2$; and

R^6 is –C=C-(optionally substituted phenyl).

2. The compound of Claim 1, wherein the compound is represented by the following structural formula:

:



or a pharmaceutically acceptable salt thereof.


3. The compound of Claim 1 or 2 wherein:

wherein the phenyl in –CH=CH-(phenyl) is optionally substituted with one or more substituents independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, (C_{1-6} aminoalkyl), (C_{1-6} alkylamino)C_{1-6} alkyl, (C_{1-6} dialkylamino)C_{1-6} alkyl, (phenyl)C_{1-6} alkyl, amino, C_{1-6} alkylamino, C_{1-6} dialkylamino, $-(CH_2)_{0-3}$-*N*-piperidinyl, $-(CH_2)_{0-3}$-*N*-morpholinyl, $-(CH_2)_{0-3}$-*N*-

pyrrolidinyl, -$(CH_2)_{0-3}$-*N*-piperazinyl and –$(CH_2)_{0-3}$-N-oxazepanyl, wherein the *N*-piperazinyl is optionally N'-substituted with C_{1-6} alkyl or C_{1-6} acyl; and

R^4 is –H or methyl.


4. The compound of Claim 1, wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.


5. The compound of Claim 1, wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

6. The compound of Claim 1, wherein the compound is represented by the following structural formula:



;

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a compound of any one of Claims 1-6 or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition of Claim 7, further comprising an additional therapeutic agent.

9. The pharmaceutical composition of Claim 8, wherein the additional therapeutic agent is an anti-cancer drug.

10. A method of treating a subject with cancer, comprising administering an effective amount of a compound of any one of Claims 1-6 or a pharmaceutically acceptable salt thereof.

11. The method of Claim 10 wherein the cancer is selected from the group consisting of lung cancer, breast cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiform, ovarian cancer, lymphoma, leukemia, melanoma, sarcoma, paraneoplasia, osteosarcoma, germinoma, glioma and mesothelioma.

12. The method of Claim 11, wherein the cancer is selected from the group consisting of lung cancer, breast cancer or colon cancer.

13. The method of Claim 12, wherein the cancer is breast cancer.


14. The method of Claim 13, wherein the cancer is basal sub-type breast cancer or a luminal B sub-type breast cancer

15. The method of Claim 14, wherein the cancer is a basal sub-type breast cancer that overexpresses PLK4.
16. The method of Claim 13, wherein the cancer is basal sub-type breast cancer that is ER, HER2 and PR negative breast cancer.
17. The method of Claim 10, wherein the cancer is a soft tissue cancer.
18. The method of Claim 17, wherein the soft tissue cancer is a sarcoma selected from the group consisting of a fibrosarcoma, a gastrointestinal sarcoma, a leiomyosarcoma, a dedifferentiated liposarcoma, a pleomorphic liposarcoma, a malignant fibrous histiocytoma, a round cell sarcoma, and a synovial sarcoma.
19. The method of claim 10 wherin the cancer is an HPV associated cancer.
20. The method of claim 19 wherein the HPV associated neoplasm is cervical cancer, anogenital cancers, head and neck cancer and oropharyngeal cancer.
21. The method of any one of Claims 10-18, further comprising co-administering an additional therapeutic agent.
22. A use of an effective amount of a compound of any one of Claims 1-6 or a pharmaceutically acceptable salt thereof for treating a subject with cancer.
23. A use of an effective amount of a compound of any one of Claims 1-6 or a pharmaceutically acceptable salt thereof for the preparations of a medicament for treating a subject with cancer.

CLAIMS


WHAT IS CLAIMED IS:

1. A compound represented by the following structural formula:




or a pharmaceutically acceptable salt thereof.

2. A compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

3. A compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and a compound of any one of Claims 1-3 or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition of claim 4 for use in treating a subject with cancer.

6. The pharmaceutical composition of claim 5 wherein the cancer is selected from the group consisting of lung cancer, breast cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiform, ovarian cancer, lymphoma, leukemia, melanoma, sarcoma, paraneoplasia, osteosarcoma, germinoma, glioma and mesothelioma.

7. The pharmaceutical composition of Claim 6, wherein the cancer is selected from the group consisting of lung cancer, breast cancer and colon cancer.

8. The pharmaceutical composition of Claim 7, wherein the cancer is basal sub-type breast cancer or a luminal B sub-type breast cancer.

9. The pharmaceutical composition of Claim 8, wherein the cancer is a basal sub-type breast cancer that overexpresses PLK4.

10. The pharmaceutical composition of Claim 7, wherein the cancer is basal sub-type breast cancer that is ER, HER2 and PR negative breast cancer.

11. The pharmaceutical composition of Claim 5, wherein the cancer is a soft tissue cancer, and the soft tissue cancer is a sarcoma selected from the group consisting of a fibrosarcoma, a gastrointestinal sarcoma, a leiomyosarcoma, a dedifferentiated liposarcoma, a pleomorphic liposarcoma, a malignant fibrous histiocytoma, a round cell sarcoma, and a synovial sarcoma.

12. The pharmaceutical composition of claim 5, wherein the cancer is an HPV associated cancer, and the HPV associated cancer is cervical cancer, anogenital cancers, head and neck cancer or oropharyngeal cancer.

13. A use of a compound of any one of Claims 1-3 or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a subject with a cancer.